What is the mechanism of action of this treatment?

The most common treatments for breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy works by killing rapidly dividing cancer cells, hormone therapy blocks hormones like estrogen that fuel certain types of breast cancer, targeted therapy attacks specific molecules involved in cancer growth, and immunotherapy boosts the body's immune system to fight cancer. Understanding these mechanisms is crucial for breast cancer patients as it helps them comprehend how their treatment works, manage side effects, and engage in informed discussions with their healthcare providers. Additionally, supportive care and peer support, as provided in the YES study, can enhance treatment adherence and improve overall quality of life by addressing emotional and psychological needs.

What side effects are associated with this type of intervention?

Common treatments for breast cancer, such as chemotherapy, endocrine therapy, and radiation therapy, have well-documented side effects. Chemotherapy can cause nausea, fatigue, hair loss, and increased infection risk. Endocrine therapy often leads to joint pain, muscle pain, hot flashes, and sleep disturbances. Radiation therapy may result in skin irritation, fatigue, and localized pain. Supportive care and peer support, as provided in the YES study, are essential for managing these symptoms and improving the quality of life for patients.

What prior FDA approvals exist?

The FDA has approved several treatments for breast cancer, particularly for HER2-positive metastatic breast cancer. Notable approvals include neratinib in combination with capecitabine, based on the NALA trial, which showed improved progression-free survival. Lapatinib plus capecitabine is another option for patients progressing on trastuzumab. These treatments align with the supportive care and research focus of the YES study, which aims to provide comprehensive care and peer support for young women with breast cancer.

What other types of research exist?

Promising alternatives to the Web-based Portal (YES) for breast cancer patients in 2024 include: 1) Mobile health apps like Belong.Life, which provide personalized support, community forums, and access to clinical trials. 2) Virtual reality platforms for stress reduction and pain management, such as those developed by AppliedVR. 3) AI-driven chatbots like Wysa, offering mental health support and coping strategies. 4) Comprehensive digital health platforms like MyCancerCoach, which offer tailored treatment information, symptom tracking, and peer support.

← Back to Search

YES Portal for Young Breast Cancer Patients (YES Trial)

N/A

Recruiting

Led By Ann H Partridge, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This study is evaluating whether a web-based portal can help young women with breast cancer.

Who is the study for?

The YES Study is for young women aged 18-39 who have been newly diagnosed with stage 0-IV breast cancer. Participants must be fluent in English, have not started treatment yet, and regularly access the internet to use a web-based platform.

What is being tested?

This study tests a web-based portal called YES designed for smartphones, tablets, and computers. It aims to monitor symptoms and behavior while providing supportive care information, peer support, and research opportunities.

What are the potential side effects?

Since this trial involves using an informational web portal rather than medication or medical procedures, traditional side effects are not applicable. However, users may experience emotional or psychological impacts from the content.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Vaginal dryness

Secondary study objectives

Adherence to Hormonal or other Oral Therapy

Adolescent and Young Adult (AYA) Concerns

Anxiety and Depression

+10 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: Newly Diagnosed Trigger Symptom InformationExperimental Treatment1 Intervention

Eligible participants are consented and enrolled and randomized into 1 or 4 groups in the study. Randomization allocation not shared directly with participant. * Participants with early stage breast cancer will respond to baseline (at enrollment) and follow-up outcome surveys via. Participants will then create a personal YES portal account and automatically receive information on sexual health and vaginal dryness. Participants will also complete serial monitoring assessments in the portal. * YES portal assessments will be sent once a week for the first 12 weeks (each assessment will take approximately 10-15 minutes). After 12 weeks of weekly assessments in YES portal, the frequency of assessments will be changed to once every month. * Surveys will be sent once every 6 months for the first 3 years, then annually. * Participants will be asked to allow for medical record review, two blood samples (baseline and 3-6 months), and a sample of any tissue available to bank.

Group II: Newly Diagnosed Automatic Symptom InformationExperimental Treatment1 Intervention

Group III: Metastatic Trigger Symptom InformationExperimental Treatment1 Intervention

Group IV: Metastatic Automatic Symptom InformationExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

YES portal

2019

N/A

~30

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy works by killing rapidly dividing cancer cells, hormone therapy blocks hormones like estrogen that fuel certain types of breast cancer, targeted therapy attacks specific molecules involved in cancer growth, and immunotherapy boosts the body's immune system to fight cancer. Understanding these mechanisms is crucial for breast cancer patients as it helps them comprehend how their treatment works, manage side effects, and engage in informed discussions with their healthcare providers. Additionally, supportive care and peer support, as provided in the YES study, can enhance treatment adherence and improve overall quality of life by addressing emotional and psychological needs.

Effects of web-based interventions on cancer patients' symptoms: review of randomized trials.Illness stories on the internet: what do breast cancer patients want at the end of treatment?Use of the internet to obtain cancer information among cancer patients at an urban county hospital.